Key Takeaways
- FDA greenlit Eli Lilly’s daily oral weight-loss medication orforglipron, marketed as Foundayo
- The drug launches April 6 through LillyDirect with $149/month self-pay pricing
- Wall Street forecasts 2026 revenues between $1.5B (Guggenheim) and $2.8B (Citi), with peak projections above $40B
- The company stockpiled $1.5B in inventory before launch to prevent supply disruptions like those affecting its injectable products
- Consensus analyst price target for LLY stands at $1,221, with predominantly Buy or Moderate Buy ratings
Eli Lilly has reached a pivotal milestone with its oral GLP-1 treatment. Federal regulators have greenlit orforglipron — commercially known as Foundayo — representing the pharmaceutical giant’s inaugural once-daily weight-loss tablet and a significant competitive move against Novo Nordisk’s market position.
During clinical studies, participants using Foundayo achieved body weight reductions of 12% to 15%. The medication operates through GLP-1 hormone targeting, utilizing the identical pathway as Novo’s Ozempic and Wegovy injectable formulations.
The pharmaceutical company plans to commence Foundayo distribution on April 6 via its LillyDirect service. Patients paying out-of-pocket will have access to the starting dosage for $149 monthly — strategically positioned to match Ozempic’s pricing.
Chief Executive David Ricks revealed that regulatory submissions for Foundayo have been filed across more than 40 nations, indicating preparations for extensive global distribution are well underway.
Financial analysts have responded with optimism. Revenue projections for 2026 span from $1.5 billion to $2.8 billion, with Citi leading the bullish camp at $2.8B and maximum annual revenues potentially surpassing $40 billion. J.P. Morgan anticipates sales hitting $6 billion by 2027.
Bernstein adopted a more measured short-term perspective, noting that complimentary sampling programs, initial lower dosing protocols and pricing considerations might pressure early revenue performance, despite potentially robust prescription volume growth. Market observers will focus intensely on weekly new-patient enrollment figures.
Foundayo offers production advantages as well. Manufacturing is simpler compared to injectable GLP-1 medications, potentially enabling Lilly to expand capacity more rapidly — especially in global markets where injectable formulations have encountered supply limitations.
Addressing Supply Chain Challenges
Lilly reports accumulating $1.5 billion in pre-launch stock, a strategic response to availability problems that affected its injectable medications Zepbound and Mounjaro. These shortages created opportunities for domestic compounding pharmacies to market alternative versions. Lilly has subsequently pursued legal remedies against compounders and medical facilities distributing products purporting to contain tirzepatide.
Novo Nordisk continues to compete aggressively. The Copenhagen-based pharmaceutical firm has countered with subscription-based pricing models and product modifications. UBS analysts estimate the combined oral portfolios from both corporations could yield approximately $5 billion in 2026, highlighting rapid category expansion within obesity therapeutics.
Morningstar forecasts oral obesity medications could represent approximately one-third of a $180 billion worldwide market by 2034.
Corporate Transaction and Expert Analysis
Lilly is simultaneously acquiring Centessa Pharmaceuticals through a transaction initially valued near $6.3 billion, broadening its portfolio into sleep-wake conditions and narcolepsy treatments. A legal practice has subsequently initiated an investor investigation regarding the Centessa transaction process, potentially creating complications before deal completion.
Regarding institutional activity, Westend Capital Management established a fresh LLY position during Q4, acquiring 16,393 shares valued at roughly $17.6 million. LLY currently comprises approximately 4.9% of Westend’s holdings.
Lilly reported Q4 earnings per share of $7.54, exceeding projections of $7.48, alongside revenue of $19.29 billion versus consensus estimates of $17.85 billion. Revenue increased 42.6% year-over-year. The corporation established fiscal 2026 EPS guidance ranging from $33.50 to $35.00.
Among 30 analysts tracking the equity, 23 assign Buy ratings, four recommend Hold, and one suggests Sell. The consensus price target reaches $1,221.26.
